Evaluation of the diagnostic potential of antibodies to beta2-glycoprotein 1 domain 1 in Chinese patients with antiphospholipid syndrome

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Zhang, Shulan ^a   Wu, Ziyan ^a   Chen, Si ^a,b   Li, Jing ^a   Wen, Xiaoting ^a   Li, Liubing ^a   Zhang, Wen ^a   Zhao, Jiuliang ^a   Zhang, Fengchun ^a   Li, Yongzhe ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BETA2 GLYCOPROTEIN 1; BIOLOGICAL MARKER; IMMUNOGLOBULIN G;

ADOLESCENT; ADULT; AGED; ANTIPHOSPHOLIPID SYNDROME; BLOOD; CHEMISTRY; CHILD; CHINA; FEMALE; HUMAN; IMMUNOLOGY; MALE; MIDDLE AGED; PREGNANCY; PROTEIN DOMAIN; SENSITIVITY AND SPECIFICITY; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIPHOSPHOLIPID SYNDROME; BETA 2-GLYCOPROTEIN I; BIOMARKERS; CHILD; CHINA; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PREGNANCY; PROTEIN DOMAINS; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

EID: 84964033719     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep23839     Document Type: Article

References (32)

1. Meroni, P. L., Borghi, M. O., Raschi, E., & Tedesco, F. Pathogenesis of antiphospholipid syndrome: understanding the antibodies. Nat Rev Rheumatol 7, 330-339 (2011)
2. Miyakis, S. et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4, 295-306 (2006)
3. De Groot, P. G., & Meijers, J. C. β (2)-Glycoprotein I: evolution, structure and function. J Thromb Haemost 9, 1275-1284 (2011)
4. De Laat, B., Derksen, R. H., Van Lummel, M., Pennings, M. T., & De Groot, P. G. Pathogenic anti-beta2-glycoprotein I antibodies recognize domain I of beta2-glycoprotein I only after a conformational change. Blood 107, 1916-1924 (2006)
5. Iverson, G. M., Victoria, E. J., & Marquis, D. M. Anti-beta2 glycoprotein I (beta2GPI) autoantibodies recognize an epitope on the first domain of beta2GPI. Proc Natl Acad Sci USA 95, 15542-15546 (1998)
6. Mahler, M., Norman, G. L., Meroni, P. L., & Khamashta, M. Autoantibodies to domain 1 of beta 2 glycoprotein 1: a promising candidate biomarker for risk management in antiphospholipid syndrome. Autoimmun Rev 12, 313-317 (2012)
7. Chighizola, C. B., Gerosa, M., & Meroni, P. L. New tests to detect antiphospholipid antibodies: anti-domain I beta-2-glycoprotein-I antibodies. Curr Rheumatol Rep 16, 402 (2014)
8. De Laat, B., Derksen, R. H., Urbanus, R. T., & De Groot, P. G. IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood 105, 1540-1545 (2005)
9. Ioannou, Y. et al. In vivo inhibition of antiphospholipid antibody-induced pathogenicity utilizing the antigenic target peptide domain I of beta2-glycoprotein I: proof of concept. J Thromb Haemost 7, 833-842 (2009)
10. De Laat, B. et al. The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study. J Thromb Haemost 7, 1767-1773 (2009)
11. Pengo, V. et al. Antiphospholipid syndrome: antibodies to Domain 1 of β 2-glycoprotein 1 correctly classify patients at risk. J Thromb Haemost 13, 782-787 (2015)
12. Bertolaccini, M. L. 14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends. Autoimmun Rev 13, 917-930 (2014)
13. Mondejar, R. Role of antiphospholipid score and anti-β 2-glycoprotein I Domain I autoantibodies in the diagnosis of antiphospholipid syndrome. Clin Chim Acta 431, 174-178 (2014)
14. Zhang, S. et al. Evaluation of the Clinical Performance of a Novel Chemiluminescent Immunoassay for Detection of Anticardiolipin and Anti-Beta2-Glycoprotein 1 Antibodies in the Diagnosis of Antiphospholipid Syndrome. Medicine (Baltimore) 94, e2059 (2015)
15. Agostinis, C. et al. A non-complement-fixing antibody to β 2 glycoprotein I as a novel therapy for antiphospholipid syndrome. Blood 123, 3478-3487 (2014)
16. Pericleous, C. Proof-of-concept study demonstrating the pathogenicity of affinity-purified IgG antibodies directed to domain I of β 2-glycoprotein I in a mouse model of anti-phospholipid antibody-induced thrombosis. Rheumatology (Oxford) 54, 722-727 (2015)
17. Colasanti, T. et al. Autoantibodies specific to a peptide of β 2-glycoprotein I cross-react with TLR4, inducing a proinflammatory phenotype in endothelial cells and monocytes. Blood 120, 3360-3370 (2012)
18. Devreese, K. M. Standardization of antiphospholipid antibody assays. Where do we stand?. Lupus 21, 718-721 (2012)
19. Rodríguez-García, V., Ioannou, Y., Fernández-Nebro, A., Isenberg, D. A., & Giles, I. P. Examining the prevalence of non-criteria antiphospholipid antibodies in patients with anti-phospholipid syndrome: a systematic review. Rheumatology (Oxford) 54, 2042-2050 (2015)
20. Roubey, R. A. Autoantibodies to phospholipid-binding plasma proteins: a new view of lupus anticoagulants and other "antiphospholipid autoantibodies. Blood 84, 2854-2867 (1994)
21. Pengo, V. et al. Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 7, 1737-1740 (2009)
22. Iverson, G. M. et al. Use of single point mutations in domain I of beta 2-glycoprotein I to determine fine antigenic specificity of antiphospholipid autoantibodies. J Immunol 169, 7097-7103 (2002)
23. Iverson, G. M. et al. Patients with atherosclerotic syndrome, negative in anti-cardiolipin assays, make IgA autoantibodies that preferentially target domain 4 of beta2-GPI. J Autoimmun 27, 266-271 (2006)
24. Arvieux, J. et al. Distinguishing features of anti-beta2 glycoprotein I antibodies between patients with leprosy and the antiphospholipid syndrome. Thromb Haemost 87, 599-605 (2002)
25. Ambrozic, A. et al. Anti-beta(2)-glycoprotein I antibodies in children with atopic dermatitis. Int Immunol 14, 823-830 (2002)
26. Andreoli, L. et al. Anti-β 2-glycoprotein I IgG antibodies from 1-year-old healthy children born to mothers with systemic autoimmune diseases preferentially target domain 4/5: might it be the reason for their innocent profile?. Ann Rheum Dis 70, 380-383 (2011)
27. Pengo, V. et al. Antibodies to Domain 4/5 (Dm4/5) of β 2-Glycoprotein 1 (β 2GP1) in different antiphospholipid (aPL) antibody profiles. Thromb Res 136, 161-163 (2015)
28. Andreoli, L. et al. Clinical characterization of antiphospholipid syndrome by detection of IgG antibodies against β 2 -glycoprotein i domain 1 and domain 4/5: ratio of anti-domain 1 to anti-domain 4/5 as a useful new biomarker for antiphospholipid syndrome. Arthritis Rheumatol 67, 2196-2204 (2015)
29. Pengo, V. et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost 8, 237-242 (2010)
30. Otomo, K. et al. Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events. Arthritis Rheum 64, 504-512 (2012)
31. Cousins, L. et al. Antibodies to domain I of β -2-glycoprotein I and IgA antiphospholipid antibodies in patients with seronegative antiphospholipid syndrome. Ann Rheum Dis 74, 317-319 (2015)
32. Mahler, M. et al. Development and performance evaluation of novel chemiluminescence assays for detection of anti-PR3 and anti- MPO antibodies. Clin Chim Acta 413, 719-726 (2012)